Ultra-high-field MRI allows for earlier diagnosis of multiple sclerosis EurekAlert! Fri, 04 May 2007 9:08 AM PDT Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.

BioMS Medical Completes Patient Recruitment in MINDSET-01 Phase II Relapsing-Remitting Multiple Sclerosis Trial RedNova Thu, 03 May 2007 2:05 PM PDT EDMONTON, May 3 /PRNewswire-FirstCall/ -- BioM

Positive Results in Tysabri Safety Study RedNova Fri, 04 May 2007 8:01 AM PDT Biogen Idec and Elan have released new study data confirming that there have been no new cases of the serious brain infection that had been linked to their multiple sclerosis drug Tysabri.

Some MS Sufferers Can Cut Coronary Artery Disease Risk With Exercise Medical News Today Thu, 03 May 2007 10:04 PM PDT Multiple sclerosis (MS) is a degenerative disease affecting the central nervous system of 400,000 Americans with 200 more diagnosed each week. The disease causes reduced nerve function and consequently a variety of symptoms. [click link for full article]

Studies Presented At Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, And High Patient ... Medical News Today Fri, 04 May 2007 0:05 AM PDT Bayer HealthCare Pharmaceuticals announced today the results of three clinical studies with Betaseron(R) (interferon beta-1b), presented this week at the American Academy of Neurology's (AAN) 59th Annual Meeting, demonstrating early efficacy, long-term tolerability, and high patient satisfaction with treatment in patients with relapsing forms of multiple sclerosis (MS). [click link for full ...

Treatment with COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active ... Business Wire via Yahoo! Finance Fri, 04 May 2007 5:00 AM PDT KANSAS CITY, Mo.----New data from a randomized, double-blind study showed that a combination of COPAXONE? along with the oral antibiotic minocycline reduced T1 Gadolinium -enhancing lesions of the brain by 63 percent in patients with active relapsing-remitting multiple sclerosis , as measured by magnetic resonance imaging , compared to those receiving COPAXONE? alone.

Xanthus Presents Novel Approach for Autoimmune Disease Reversal With Symadex RedNova Thu, 03 May 2007 12:01 PM PDT Xanthus Pharmaceuticals, Inc today presented data demonstrating that Symadex? reversed the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis. The presentation was made by Stephen J.

BioMS drug for MS in phase 2 UPI Thu, 03 May 2007 12:58 PM PDT U.S. firm BioMS Medical said Thursday it has finished enrollment in its MINDSET-01 trial of a drug for multiple sclerosis.

COPAXONE(R) Treatment Over Two Years After Short Term Induction With Mitoxantrone Provided Sustained Benefits to Active ... RedNova Fri, 04 May 2007 7:02 AM PDT New data have demonstrated that relapsing-remit

Friday's Health Winners & Losers
TheStreet.com Fri, 04 May 2007 10:40 AM PDT
ISTA Pharmaceuticals plunged following an FDA rejection, helping keep health stocks flat.